Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Fennec Pharmaceuticals (FENC) Net Margin (2020 - 2025)

Fennec Pharmaceuticals filings provide 4 years of Net Margin readings, the most recent being 15.48% for Q4 2025.

  • On a quarterly basis, Net Margin rose 3442.0% to 15.48% in Q4 2025 year-over-year; TTM through Dec 2025 was 6.29%, a 667.0% decrease, with the full-year FY2025 number at 21.82%, down 4718.0% from a year prior.
  • Net Margin hit 15.48% in Q4 2025 for Fennec Pharmaceuticals, up from 5.0% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 50.86% in Q1 2024 to a low of 355.34% in Q1 2023.
  • Median Net Margin over the past 3 years was 27.04% (2023), compared with a mean of 61.04%.
  • Biggest five-year swings in Net Margin: skyrocketed 40619bps in 2024 and later crashed -6416bps in 2025.
  • Fennec Pharmaceuticals' Net Margin stood at 26.89% in 2023, then grew by 30bps to 18.94% in 2024, then surged by 182bps to 15.48% in 2025.
  • The last three reported values for Net Margin were 15.48% (Q4 2025), 5.0% (Q3 2025), and 32.69% (Q2 2025) per Business Quant data.